AbstractObjective: To analyze the effect of amifostine combined with gemcitabine + cisplatin (GP) regimen on short-term efficacy and adverse reactions of chemotherapy in patients with advanced breast cancer. Methods: The clinical data of 66 patients with advanced breast cancer diagnosed by pathology and cytology from July 2017 to December 2018 were analyzed retrospectively. 66 patients were divided into control group (30 cases) receiving GP treatment and combined group (36 cases) treated by amifostine combined with GP. The short-term efficacy and adverse reactions of chemotherapy were compared between the two groups. Results: There was no significant difference in total effective rate and disease control rate between the two groups (both P> 0.05). There was no significant difference in the incidence of nausea, vomiting, dizziness, liver dysfunction and renal dysfunction between the two groups (all P>0.05), but the incidence rate of peripheral neurotoxicity and myelosuppression in the combined group was significantly lower than that in the control group (both P<0.05). Conclusion: The short-term efficacy of amifostine combined with GP regimen in the treatment of advanced breast cancer is similar to that of GP regimen alone, but amifostine combined with GP regimen can effectively decrease the incidence rate of peripheral nerve toxicity and myelosuppression, and does not cause serious adverse reactions of chemotherapy, with good tolerance of patients.
QIN Xuejin,HAN Ke. Effect of Amifostine combined with GP Regimen on the Short-term Efficacy and Adverse Reactions of Chemotherapy in Patients with Advanced Breast Cancer[J]. HeBei Med, 2019, 25(12): 1950-1953.
[1] Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur Cancer,2009,45(2):228~247. [2] 白云,陶阳,王崇杰,等.应用奥沙利铂联合替吉奥以及吉西他滨联合顺铂方案对晚期三阴性乳腺癌的疗效与不良反应比较[J].中国生化药物杂志,2017,37(4):293~295. [3] 武帅,王志敏,刘赟,等.氨磷汀联合右丙亚胺降低蒽环类药物心脏毒性的临床观察[J].中西医结合心脑血管病杂志,2017,15(20):2611~2612. [4] Ranganathan K, Simon E, Lynn J, et al.Novel formulation strategy to improve the feasibility of amifostine administration[J].Pharm Res,2018,35(5):99. [5] Ormsby RJ, Lawrence MD, Blyth BJ, et al. Protection from radiation-induced apoptosis by the radioprotector amifostine (WR-2721) is radiation dose dependent[J].Cell Biol Toxicol,2014,30(1):55~66. [6] 魏妙华,徐益元,陈健苗,等.GP方案单用与联合氨磷汀方案在晚期恶性肿瘤化疗不良反应中的比较[J].中国临床药学杂志,2015,24(1):39~42.
2019, Vol. 25 
